

Amendments to the Specification:

Please replace the paragraph (or section) beginning at page 1, line 5, with the following redlined paragraph (or section):

This application is related to U.S. Patent Application No. 09/852,911, filed May 9, 2001, now abandoned; U.S. Patent Application No. 09/780,669, filed February 9, 2001; U.S. Patent Application No. 09/759,143, filed January 12, 2001; U.S. Patent Application No. 09/709,729, filed November 9, 2000 now abandoned; U.S. Patent Application No. 09/685,166, filed October 10, 2000, now Patent No. 6,630,305; U.S. Patent Application No. 09/679,426, filed October 2, 2000, now Patent No. 6,759,515; U.S. Patent Application No. 09/657,279, filed September 6, 2000; and U.S. Application No. 09/651,236, filed August 29, 2000; U.S. Application No. 09/636,215, filed August 9, 2000; U.S. Application No. 09/605,783, filed June 27, 2000; U.S. Application No. 09/593,793, filed June 13, 2000; U.S. Application No. 09/570,737, filed May 12, 2000; U.S. Application No. 09/568,100, filed May 9, 2000; U.S. Application No. 09/536,857, filed March 27, 2000; U.S. Application No. 09/483,672, filed January 14, 2000; U.S. Application No. 09/443,686, filed November 18, 1999; U.S. Application No. 09/439,313, filed November 12, 1999; U.S. Application No. 09/352,616, filed July 13, 1999; U.S. Application No. 09/288,946, filed April 9, 1999; U.S. Application No. 09/232,149, filed January 15, 1999; U.S. Application No. 09/159,812, filed September 23, 1998; U.S. Application No. 09/115,453, filed July 14, 1998; U.S. Application No. 09/030,607, filed February 25, 1998; U.S. Application No. 09/020,956, filed February 9, 1998; U.S. Application No. 08/904,804, filed August 1, 1997 (abandoned); U.S. Application No. 08/806,099, filed February 25, 1997 (abandoned); each a CIP of the previously filed application and pending unless noted, and all incorporated in their entirety herein by reference.

Please replace the paragraph (or section) beginning at page 10, line 20, with the following redlined paragraph (or section):

Figure 8 illustrates the results of epitope mapping studies on P501S. The peptides used in the study are shown from left to right at the bottom of the figure, as follows:

MDRLVQRPGTRAVYLASVA (SEQ ID NO: 489), YLASVAAFPVAAGATCLSHS (SEQ ID NO: 490), TCLSHSVAVVTASAALTGFT (SEQ ID NO: 491), ALTGFTFSALQILPYTLASL (SEQ ID NO: 492), YTLASLYHREKQVFLPKYRG (SEQ ID NO: 493), LPKYRGDTGGASSEDSLMIS (SEQ ID NO: 494), DSLMTSFLPGPKPGAPFPNG (SEQ ID NO: 495), APFPNGHVGAGGSGLLPPPA (SEQ ID NO: 496), LLPPPPALCGASACDVSVRV (SEQ ID NO: 497), DVSVRVVVGEPTEARVVPGR (SEQ ID NO: 498), RVVPGRGICLDLAILDSAFL (SEQ ID NO: 499), LDSAFLLSQVAPSLFMGSIV (SEQ ID NO: 500), FMGSIVQLSQSVTAYMVSAA (SEQ ID NO: 501).

Please replace the paragraph (or section) beginning at page 10, line 21, with the following redlined paragraph (or section):

Figure 9 is a schematic representation of the P501S protein (SEQ ID NO:113) showing the location of transmembrane domains and predicted intracellular and extracellular domains.

Please replace the paragraph (or section) beginning at page 10, line 26, with the following redlined paragraph (or section):

Figure 11 shows the results of an ELISA assay to determine the specificity of rabbit polyclonal antisera raised against P501S. The depicted sequence corresponding to peptide P501S 306-320 is set forth in SEQ ID NO: 519 and the sequence corresponding to P501S 296-320 is set forth in SEQ ID NO: 520.